Valproic Acid-induced Hyperammonemic Encephalopathy Promoted by Levetiracetam
Sook Young Roh, Hyun-soon Jang, Eun Hye Jeong, Byung-Su Kim, Moon Kyung Sunwoo
J Epilepsy Res. 2014;4(2):82-84. Published online 2014 Dec 31 DOI: https://doi.org/10.14581/jer.14017
Citations to this article as recorded by 
Risk factors of hyperammonemia in epilepsy patients with valproic acid therapy
Dong Won Kwack, Dong Wook Kim
Clinical Neurology and Neurosurgery.2023; 233: 107962. CrossRef
Hyperammonemic Encephalopathy Associated with Perampanel: Case Report and Discussion
Paula T. Marques, Quratulain Zulfiqar Ali, Arunan Selvarajah, Hanna Faghfoury, Richard A. Wennberg, Danielle M. Andrade
Canadian Journal of Neurological Sciences / Journa.2021; 48(3): 438. CrossRef
Valproic acid-induced encephalopathy: A review of clinical features, risk factors, diagnosis, and treatment
Junhong Wu, Jiyuan Li, Wei Jing, Xin Tian, Xuefeng Wang
Epilepsy & Behavior.2021; 120: 107967. CrossRef
Estatus epiléptico no convulsivo secundario a encefalopatía hiperamonémica inducida por valproato
A. Viloria Alebesque, N. Montes Castro, C. Arcos Sánchez, D. Vicente Gordo
Neurología.2020; 35(8): 603. CrossRef
Non-convulsive status epilepticus secondary to valproate-induced hyperammonaemic encephalopathy
A. Viloria Alebesque, N. Montes Castro, C. Arcos Sánchez, D. Vicente Gordo
Neurología (English Edition).2020; 35(8): 603. CrossRef
Effects of levetiracetam and valproic acid treatment on liver function tests, plasma free carnitine and lipid peroxidation in childhood epilepsies
Pınar Haznedar, Özlem Doğan, Pelin Albayrak, Gökçen Öz Tunçer, Serap Teber, Gülhis Deda, F. Tuba Eminoglu
Epilepsy Research.2019; 153: 7. CrossRef
Levetiracetam (Keppra): Evidence-Based Polypharmacy in Two Patients With Epilepsy
Zahra Tolou-Ghamari
Jundishapur Journal of Chronic Disease Care.2016;[Epub] CrossRef